Does expression of PD-L1 identify a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung?
Should the expression of PD-L1 be on the verge of becoming an additional biomarker for routine diagnostics in NSCLC, our findings will provide important further insight and could contribute towards more effectively stratifying patients. These results may single out certain patient groups with a potential for increased benefit from anti PD-1/PD-L1 treatment strategies and should be considered in future trials.
Use of femoral venous catheters is a major risk factor for catheter-related bloodstream infection in CRS.